We had the pleasure to speak with Coleen Cunningham (Duke University School of Medicine, Durham, NC, US) to discuss the development of VRC07-523LS for the prevention of HIV in infants and children.
The abstract entitled: ‘Safety and PK of Potent Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants’ (OA03.02) was presented at the HIVR4P Virtual Conference 2021, 27 January 2021.
Coleen Cunningham would like to thank all individuals involved in the study and sites, and would also like to recognize all the parents and children involved in the study for their contribution.
- What are the major unmet needs in prevention of HIV in infants and children? (0:11)
- What is the rationale for the administration of broadly neutralizing, monoclonal antibodies (mAb) to HIV-exposed infants? (0:42)
- What is VRC07-523LS and what are its potential advantages compared with other mAbs? (1:44)
- Could you tell us a little about the study you are presenting, and its safety and tolerability findings? (3:15)
- What will be the next steps in the clinical development of VRC07-523LS? (4:23)
Disclosures: Coleen Cunningham has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the HIVR4P 2021 Virtual Meeting.
Share this Video
Related Videos In HIV
18th European AIDS Conference 2021: Welcome from Sanjay Bhagani
Dr Sanjay Bhagani invites you to join the 18th European AIDS Conference (EACS 2021). The conference will be organised in a hybrid format from October 27-30, 2021. The onsite Conference in London will take place, following a comprehensive COVID-19 health and safety concept, complemented by an engaging and interactive online platform that mirrors the scientific […]
Kelly Dooley, ECCMID 2021: Challenges in Developing New Treatments for Drug-resistant Tuberculosis
It was a pleasure to meet with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the major challenges to developing new treatment regimens for drug-resistant tuberculosis. The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious […]
David Lawrence, IAS 2021: Phase 3 AMBITION Trial Results
We had the pleasure to meet with David Lawrence (London School of Hygiene and Tropical Medicine, London, UK) to discuss the phase 3 AMBITION trial results investigating liposomal amphotericin for treatment of HIV-associated Cryptococcal Meningitis. The abstract entitled: ‘Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!